Status:
RECRUITING
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
Lead Sponsor:
University of Chicago
Conditions:
Metastatic Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
A randomized research study of drugs nivolumab and pembrolizumab in patients with locally advanced or metastatic cancers. Based on data from earlier studies it appears that the drugs can be given less...
Eligibility Criteria
Inclusion
- Patients with locally advandced or metastatic cancer whose physician has determined they are candidates for treatment with nivolumab or pembrolizumab
- 18 years old or older
- Measurable disease per RECIST criteria
Exclusion
- Patients who have previously received immune checkpoint inhibitors or investigational monoclonal antibody therapy.
- Patients whose treatment plan is to receive ipilimumab or other anti-CTLA4 monoclonal antibody in combination with either nivolumab or pembrolizumab.
- Ipilimumab and nivolumab combination are not eligible for this trial.
- (Note: Patients whose planned treatment is the combination of anti-PD-1 and tyrosine kinase inhibitor such as pembrolizumab-axitinib or the combination of traditional cytotoxic chemotherapy and anti-PD-1 are eligible)
Key Trial Info
Start Date :
June 25 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 12 2026
Estimated Enrollment :
264 Patients enrolled
Trial Details
Trial ID
NCT04295863
Start Date
June 25 2020
End Date
April 12 2026
Last Update
October 1 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University Of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, United States, 60637
2
SSM Health Cancer Care
Madison, Wisconsin, United States, 53717